A Clinical Study to Assess the Effect of Different Dosing Intervals on the Multiple-Dose Pharmacokinetics of WD-1603 (25mg Carbidopa/150mg Levodopa) When Administered Before Meals in Healthy Participants

Shanghai WD Pharmaceutical Co., Ltd.1 个研究点分布在 1 个国家目标入组 12 人开始时间: 2026年3月17日最近更新: 2026年9月23日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 12
试验地点: 1
主要终点: Maximal Plasma Concentration (Cmax) of Carbidopa and Levodopa

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy volunteers. We also want to learn about the safety of WD-1603.

The main question we want to answer is:

How does the body process WD-1603 when it is taken by different time intervals? What will participants do?
Participants will take one tablet of WD-1603 twice a day on three separate days.
On each dosing day, the two doses will be spaced different hours apart.
Between each dosing day, there will be a rest period of up to 7 days.

详细描述

This trial is a multiple-dose, open-label, sequential, three-period pharmacokinetic study comparing different dosing intervals of WD-1603 in healthy participants.

The purpose of the study is:

To evaluate the effect of different dosing intervals on the pharmacokinetics of twice-daily WD-1603 when administered before meals.
To assess the safety and tolerability of WD-1603 in healthy participants. Each participant will receive the investigational drug in the sequence of Treatment A, Treatment B, and Treatment C. After each dosing period, there will be a washout period of up to 7 days.

This Phase I clinical trial is planned to enroll 12 healthy participants, with an appropriate proportion of female participants (at least one quarter, i.e., 3 participants).

Pharmacokinetic parameters will be calculated using Phoenix WinNonlin (version 8.3 or higher), and other analyses will be performed using SAS software (version 9.4 or higher). Using PKS, an analysis of variance (ANOVA) is performed on the natural log-transformed Cmax, AUC0-τ, and ΔC0.5. The model includes dosing occasion as a fixed effect and participant as a random effect. The 90% confidence interval for the geometric mean ratio (second dose/first dose) of each parameter is calculated.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Healthy adult male or female participants aged 18 to 55 years (inclusive) at the time of signing the informed consent form (ICF).
•Body weight: male ≥ 50 kg, female ≥ 45 kg; body mass index (BMI) between 18 and 27 kg/m² (inclusive) (BMI = weight [kg] / height² [m²]).
•Medical history inquiry, physical examination, vital signs, laboratory tests (complete blood count, urinalysis, blood biochemistry, serological virology tests, coagulation function), 12-lead ECG, intraocular pressure measurement, abdominal ultrasound, and chest X-ray during the screening period are all within normal ranges or clinically insignificant if outside normal ranges.
•Participants (including their spouses or partners) have no plans for conception or for donating sperm/eggs from the time of signing the ICF (for females)/first dosing (for males) until 3 months after the last dose, and voluntarily agree to use effective non-pharmacological contraception during the trial period.
•Fully understand the trial content, procedures, and potential adverse reactions, voluntarily agree to participate, and sign the ICF before any trial-related procedures begin.
•Able to communicate well with the investigators and capable of understanding and complying with the requirements of this trial.

排除标准

•Allergy-prone constitution, history of allergic diseases, or known severe allergic reaction or allergy history to levodopa/carbidopa or related medications.
•Drug use within 3 months prior to screening, history of drug abuse, or positive urine drug abuse screening (morphine, methamphetamine, ketamine, methylenedioxymethamphetamine, tetrahydrocannabinol acid, cocaine).
•History of glaucoma, cancer, diabetes mellitus, bronchial asthma, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, hematological, dermatological, endocrine, neuropsychiatric diseases, or other significant conditions.
•Dysphagia or any condition that may affect drug absorption (e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy), or gastrointestinal diseases causing clinically significant symptoms such as nausea, vomiting, diarrhea, or malabsorption syndrome.
•History of orthostatic hypotension.
•Any relevant medical history, surgical history, or trauma within 3 months prior to the first dose that may affect trial safety or drug pharmacokinetics, or planned surgery during the trial period.
•Use of prescription drugs, over-the-counter medications, health products, Chinese herbal medicines, or dietary supplements within 4 weeks prior to the first dose, especially monoamine oxidase inhibitors (e.g., phenelzine, rasagiline, selegiline, brofaromine, toloxatone, isocarboxazid, etc.).
•Participation in any clinical trial and receipt of investigational drugs within 3 months prior to the first dose.
•Blood donation (including component blood) or significant blood loss (≥400 mL), blood transfusion, or use of blood products within 3 months prior to the first dose.
•Difficulty with venous access, unsuitability or unwillingness to use intravenous catheters, or history of needle/blood phobia.
•Heavy smokers or average daily cigarette consumption of more than 10 cigarettes within 3 months prior to screening.
•Alcohol consumption exceeding 21 standard units per week within 3 months prior to screening (1 standard unit contains 14g of alcohol, e.g., 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine), positive alcohol breath test, or unwillingness to abstain from alcohol from 48 hours before the first dose of each period until the completion of blood sampling for that period.
•Estimated glomerular filtration rate (eGFR) < 90 mL/min·1.73m² during the screening period.
•During screening: systolic blood pressure < 90 mmHg or ≥ 140 mmHg, diastolic blood pressure < 60 mmHg or ≥ 90 mmHg, pulse rate > 100 beats/min or < 50 beats/min.
•History of prolonged QT interval or other clinically significant cardiac diseases, or QTcF ≥ 450 ms on ECG during screening.
•Symptoms of acute infection (e.g., influenza) or acute gastroenteritis within 2 weeks prior to screening, or history of vomiting or diarrhea within 1 week prior to screening.
•Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody.
•Currently pregnant (including positive pregnancy test) or lactating female.
•Poor compliance as judged by the investigator, or other factors deemed unsuitable for participation in this trial.

研究组 & 干预措施

WD-1603 (25 mg/150 mg) 6-hour interval

Experimental

Cohort 2: Participants will take one WD-1603 25 mg/150 mg tablet orally 5 minutes before each meal, twice daily with a 6-hour interval between doses, over a 1-day dosing period.

干预措施: Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg) (Drug)

WD-1603 (25 mg/150 mg) 7-hour interval

Experimental

Cohort 3: Participants will take one WD-1603 25 mg/150 mg tablet orally 5 minutes before each meal, twice daily with a 7-hour interval between doses, over a 1-day dosing period.

干预措施: Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg) (Drug)

WD-1603 (25 mg/150 mg) 5-hour interval

Experimental

Cohort 1: Participants will take one WD-1603 25 mg/150 mg tablet orally 5 minutes before each meal, twice daily with a 5-hour interval between doses, over a 1-day dosing period.

干预措施: Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg) (Drug)